
FDA Approves First Treatment for KRAS-Mutated Recurrent LGSOC
The FDA Thursday granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack; Verastem Oncology) for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who received prior systemic …